Nektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of $0.53, $0.14 better than the analyst estimate of $0.39. Revenue for the quarter came in at $132.9 million versus the consensus estimate of $123.2 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.